All manuscripts
Publications CAR T Cells

A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers

Published Journal Nature Communications

Share
No image preview

Overview

Development of BAFF ligand-based CAR-T cells targeting BAFF-R, BCMA, and TACI. Cells were modified using the TcBuster transposon system and maintained in G-Rex® culture vessels.

What this paper found

A chimeric antigen receptor built from the BAFF ligand gave a single T cell product the ability to engage BAFF-R, BCMA and TACI and to kill mantle cell lymphoma, acute lymphoblastic leukemia and multiple myeloma cells. The receptor was delivered without a virus, using the TcBuster transposon system, and the engineered T cells were expanded in gas-permeable rapid expansion vessels. At a 5:1 effector:target ratio, 69% of Jeko-1 and 57% of rs4;11 cells were killed, while HEK293T lines engineered to express any single BAFF receptor were lysed and parental cells were spared. Transposon copy number stayed below 10 copies per CAR-positive cell and clonal outgrowth was low. In mice, treated animals survived significantly longer in mantle cell lymphoma xenografts and carried less tumor in myeloma and leukemia models.

Note: The efficacy data come from cell line assays and mouse xenograft models, and the authors note that no head-to-head comparison was run against existing APRIL-based or scFv-based CARs.

Overall, we have demonstrated the effectiveness of a BAFF ligand-based CAR-T cells, generated using non-viral methods, in killing ALL, MCL, and MM cells in vitro and in vivo. — Derek P. Wong, Nand K. Roy, Keman Zhang, Anusha Anukanth, Abhishek Asthana, Nicole J. Shirkey-Son, Samantha Dunmire, Bryan J. Jones, Walker S. Lahr, Beau R. Webber, Branden S. Moriarity, Paolo Caimi, Reshmi Parameswaran, Nature Communications

Study details

Authors
Derek P. Wong, Nand K. Roy, Keman Zhang, Anusha Anukanth, Abhishek Asthana, Nicole J. Shirkey-Son, Samantha Dunmire, Bryan J. Jones, Walker S. Lahr, Beau R. Webber, Branden S. Moriarity, Paolo Caimi, Reshmi Parameswaran
Institution
Department of Pathology, Case Western Reserve University, Cleveland, OH, USA · Division of Hematology/Oncology, Department of Medicine, Case Western Reserve University, Cleveland, OH, USA · Division of Pediatric Hematology/Oncology, Angie Fowler AYA Cancer Institute, UH Rainbow Babies & Children's Hospital, Cleveland, OH, USA · Luminary Therapeutics, Minneapolis, MN, USA · Bio-Techne, Minneapolis, MN, USA · Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA · Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA · Center for Genome Engineering, University of Minnesota, Minneapolis, MN, USA · Stem Cell Institute, University of Minnesota, Minneapolis, MN, USA · The Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA
Journal
Nature Communications
Year
2022
PMID / PMC
PMID: 35017485 · PMC
Cell type(s)
CAR T Cells
Application area
Hematologic malignancy
Study phase
Preclinical

How G-Rex® was used

T cells electroporated with TcBuster transposase mRNA and the BAFF-CAR transposon plasmid were maintained in gas-permeable rapid expansion (G-Rex®) culture vessels from Wilson Wolf. The expansion medium was CTS OpTmizer T-cell expansion SFM with 2.5% CTS Immune Cell SR, 2 mM L-glutamine, 10 mM N-acetyl-L-cysteine, 5 ng/mL IL-7 and 5 ng/mL IL-15, at 37 °C and 5% CO2. BAFF CAR-T cells were expanded for 7 days and then cryopreserved, and cells thawed from those lots kept stable surface BAFF-CAR expression for 21 days in culture.

Ecosystem products: TcBuster

Explore related

Full citation

Wong DP, Roy NK, Zhang K, et al. A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers. Nat Commun. 2022;13(1):217.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →